Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Paul B. Eckburg, MD

Consultant
Spero Therapeutics

Disclosure(s): AN2 Therapeutics: Stocks/Bonds; Spero Therapeutics: Advisor/Consultant

Poster(s):

222 - Clinical and microbiological outcomes for Enterobacterales uropathogens in the Phase 3 ADAPT-PO Study of oral tebipenem pivoxil hydrobromide
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
2236 - Effectiveness of TBP-PI-HBr in Patients with Instrumentation, Anatomic or Functional Abnormalities: Secondary Analysis from ADAPT-PO
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET